<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01079962</url>
  </required_header>
  <id_info>
    <org_study_id>EMD 084000-505</org_study_id>
    <nct_id>NCT01079962</nct_id>
  </id_info>
  <brief_title>An Active-controlled, Clinical Trial to Assess Central Hemodynamic Effects of Bisoprolol in Hypertensive Patients (Central Hemodynamic Assessment Measured in Patient With HypertensION [CHAMPION])</brief_title>
  <official_title>A Prospective, Multi-center, Randomized, Open-label, Clinical Trial to Compare the Aortic Pulse Pressure Effects of Bisoprolol and Atenolol in 12 Weeks Treatment of Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck KGaA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Merck KGaA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Antihypertensive drugs aim to reduce blood pressure (BP) either through decrease of the total
      peripheral resistance through vasodilatation at the level of arterioles (microcirculation) or
      by decreasing the cardiac output through reduction of the stroke volume or heart rate or
      both. On the other hand, all antihypertensive drugs might potentially decrease arterial
      stiffness passively with the reduction of the distending pressure or with the
      resynchronization of the reflected pressure wave. With theses potential mechanisms, it is
      also expected that these drugs might exert a favorable effect on pulse pressure amplification
      between central and peripheral arteries.

      However, there is solid evidence that the widely applied antihypertensive drugs have
      differential effect on brachial and central BP. Several reports in the past have confirmed
      the potential hypothesis that beta blockers decrease central BP less than the observed
      reduction at the level of the brachial artery. It has been hypothesized that deceleration of
      heart rate and the re synchronizing the reflected pressure wave earlier in the systolic phase
      seems to be the leading cause of non-favorable effect of beta blockers on central BP, these
      effects might be partially counterbalanced in beta blockers with high beta-1 selectivity
      resulting in less peripheral vasoconstriction properties.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Central pulse pressure is a better predictor of left ventricular mass and carotid intima
      thickness, and the conventional peripheral BP does not seem to be an accurate reflection of
      central arterial BP. The pulse pressure amplification between peripheral and central arteries
      reflects the left ventricular afterload, subendothelial viability, and the intensity of
      cyclic stress imposed to the renal and cerebral micro- and macro vessels. As central
      hemodynamic parameters are independently associated with organ damage and are closely related
      to important cardiovascular outcome, it is suggested that the new clinical trials on
      antihypertensive drug treatment should compare simultaneously the chronic effect of drugs on
      both peripheral and central BP.

      OBJECTIVES

      Primary objective:

        -  To assess the effect of bisoprolol versus atenolol on the aortic pulse pressure as a
           central hemodynamic index in subjects with hypertension

      Secondary objectives:

        -  To assess the effect of bisoprolol versus atenolol on the aortic BP as a central
           hemodynamic index in subjects with hypertension

        -  To assess the effect of bisoprolol versus atenolol on the AIx and cfPWV as arterial
           stiffness indexes in subjects with hypertension

        -  To assess the effect of bisoprolol versus atenolol on the aortic pulse pressure as a
           central hemodynamic index at interim visit (Visit 4)

        -  To assess the effect of bisoprolol versus atenolol on the lipid profile and serum
           glucose as metabolism indexes

        -  To assess the effect of bisoprolol versus atenolol on the brachial BP as a peripheral BP
           index in subjects with hypertension

        -  To assess the safety and tolerability of bisoprolol versus atenolol in subjects with
           hypertension

      The present study will be approximately of 14 weeks duration comprising of 1 week screening,
      followed by a 12 weeks treatment period and a 2 weeks post study follow up contact conducted
      via telephone to monitor additional serious adverse experiences.

      There will be 4 scheduled visits (at Day -7, Day 0, Week 4 and Week 12). After screening
      period in which eligibility criteria were confirmed, subjects with hypertension will be
      randomized in a 1:1 ratio to receive treatment with either bisoprolol or atenolol.
      Hemodynamic measurements will be made at baseline, Week 4, Week 12 and biochemical
      measurements will be made at baseline (Day 0) and at Week 12.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Aortic Pulse Pressure (APP) in Intention to Treat (ITT) Population at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The APP was calculated as aortic systolic pressure minus aortic diastolic pressure. The change in APP at Week 12 was calculated as APP at Week 12 minus APP at baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Aortic Pulse Pressure (APP) in Per Protocol (PP) Population at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The APP was calculated as aortic systolic pressure minus aortic diastolic pressure. The change in APP at Week 12 was calculated as APP at Week 12 minus APP at baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Aortic Blood Pressure (BP) at Week 4 and Week 12</measure>
    <time_frame>Baseline, Week 4 and Week 12</time_frame>
    <description>The change in aortic BP (aortic systolic blood pressure [SBP], aortic diastolic blood pressure [DBP] and aortic mean blood pressure [BP]) at Week 4 and Week 12 was calculated as aortic BP (aortic SBP, aortic DBP and aortic mean BP) at Week 4 and Week 12 minus aortic BP (aortic SBP, aortic DBP and aortic mean BP) at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Aortic Augmentation Index (AIx) at Week 4 and Week 12</measure>
    <time_frame>Baseline, Week 4 and Week 12</time_frame>
    <description>Augmentation index is a composite measure of wave reflection and systemic arterial stiffness which was calculated as the difference between the second and first systolic peaks. The change in AIx at Week 4 and Week 12 was calculated as AIx at Week 4 and Week 12 minus AIx at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Carotid-femoral Pulse Wave Velocity (cfPWV) at Week 4 and Week 12</measure>
    <time_frame>Baseline, Week 4 and Week 12</time_frame>
    <description>Pulse wave velocity (PWV) is used as a measure of arterial stiffness, which is a measure of the cushioning functioning of major vessels like the aorta. The velocity of the Pulse wave (PW) along an artery is dependent on the stiffness of that artery. The change in cfPWV at Week 4 and Week 12 was calculated as cfPWV at Week 4 and Week 12 minus cfPWV at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Heart Rate at Week 4 and Week 12</measure>
    <time_frame>Baseline, Week 4 and Week 12</time_frame>
    <description>The change in heart rate at Week 4 and Week 12 was calculated as heart rate at Week 4 and Week 12 minus heart rate at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Aortic Pulse Pressure (APP) at Week 4</measure>
    <time_frame>Baseline and Week 4</time_frame>
    <description>The APP was calculated as aortic systolic pressure minus aortic diastolic pressure. The change in APP at Week 4 was calculated as APP at Week 4 minus APP at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Lipid Levels at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The lipid levels evaluated were total cholesterol, low density lipoprotein (LDL) cholesterol, and high density lipoprotein (HDL) cholesterol blood concentrations. The change in lipid levels at Week 12 was calculated as lipid levels at Week 12 minus lipid levels at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Blood Glucose Levels at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The change in blood glucose level at Week 12 was calculated as blood glucose level at Week 12 minus blood glucose level at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Brachial Blood Pressure (BP) at Week 4 and Week 12</measure>
    <time_frame>Baseline, Week 4 and Week 12</time_frame>
    <description>The change in brachial BP (brachial SBP, brachial DBP and brachial mean BP) at Week 4 and Week 12 was calculated as brachial BP (brachial SBP, brachial DBP and brachial mean BP) at Week 4 and Week 12 minus brachial BP (brachial SBP, brachial DBP and brachial mean BP) at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events (AEs)</measure>
    <time_frame>Baseline up to Week 14 (follow-up visit)</time_frame>
    <description>An adverse event (AE) was defined as any untoward medical occurrence in the form of signs, symptoms, abnormal laboratory findings, or diseases that emerges or worsens relative to baseline during a clinical study with an Investigational Medicinal Product (IMP), regardless of causal relationship and even if no IMP has been administered.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">209</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Bisoprolol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Atenolol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bisoprolol</intervention_name>
    <description>Bisoprolol tablet will be administered orally at a dose of 5 milligram (mg) once daily in the morning for 12 weeks.</description>
    <arm_group_label>Bisoprolol</arm_group_label>
    <other_name>CONCOR®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atenolol</intervention_name>
    <description>Atenolol tablet will be administered orally at a dose of 50 mg once daily in the morning for 12 weeks.</description>
    <arm_group_label>Atenolol</arm_group_label>
    <other_name>TENORMIN®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  An antihypertensive-naive subject or a subject who has not been taking the previously
             administered antihypertensive agent for at least 4 weeks prior to screening

          -  Subjects aged between 20 and 75 years, inclusive

          -  Subjects with systolic blood pressure (SBP) greater than or equal to 140 millimeter of
             mercury (mmHg) and less than 180 mmHg or diastolic blood pressure (DBP) greater than
             or equal to 90 mmHg and less than 110 mmHg

        Exclusion Criteria:

          -  Subjects with secondary hypertension

          -  Subjects with renal impairment (Creatinine greater than 150 micromoles/liter [mcmol/L]
             or Creatinine greater than 1.7 mg/deciliter [dL])

          -  Subjects with severe hypertension (Stage III) SBP greater than or equal to 180 mmHg or
             DBP greater than or equal to 110 mmHg

          -  Subjects with congestive heart failure, acute myocardial infarction, unstable angina

          -  Subjects with moderate bronchial asthma, chronic obstructive pulmonary disease

          -  Subjects with symptomatic bradycardia, radial artery injury, second degree or third
             degree atrioventricular (AV) block, atrial fibrillation, atrial flutter, left bundle
             branch block (LBBB)

          -  Subjects with a history of hypersensitivity to bisoprolol and atenolol products

          -  Pregnancy or breastfeeding women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Responsible</last_name>
    <role>Study Director</role>
    <affiliation>Merck Ltd., Korea, an affiliate of Merck KGaA, Darmstadt, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Severance Hosptial, 250, Seongsanno, Seodaemungu</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 2, 2010</study_first_submitted>
  <study_first_submitted_qc>March 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2010</study_first_posted>
  <results_first_submitted>August 30, 2012</results_first_submitted>
  <results_first_submitted_qc>August 30, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 2, 2012</results_first_posted>
  <last_update_submitted>January 20, 2014</last_update_submitted>
  <last_update_submitted_qc>January 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bisoprolol</keyword>
  <keyword>Atenolol</keyword>
  <keyword>Hypertension</keyword>
  <keyword>Blood pressure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atenolol</mesh_term>
    <mesh_term>Bisoprolol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 228 participants were screened for the study, out of which 19 were screen failures and 209 participants received the study medication.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Bisoprolol</title>
          <description>Single dose of bisoprolol tablet (CONCOR®) administered orally at a dose of 5 milligram (mg) daily every morning for 12 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Atenolol</title>
          <description>Single dose of atenolol tablet (TENORMIN®) administered orally at a dose of 50 mg daily every morning for 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="105"/>
                <participants group_id="P2" count="104"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="90"/>
                <participants group_id="P2" count="89"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No blood pressure (BP) control</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Inclusion/exclusion criteria</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant not returning for next visit</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Due to arrhythmia/bradycardia</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Bisoprolol</title>
          <description>Single dose of bisoprolol tablet (CONCOR®) administered orally at a dose of 5 milligram (mg) daily every morning for 12 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Atenolol</title>
          <description>Single dose of atenolol tablet (TENORMIN®) administered orally at a dose of 50 mg daily every morning for 12 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="105"/>
            <count group_id="B2" value="104"/>
            <count group_id="B3" value="209"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.0" spread="11.2" lower_limit="25" upper_limit="74"/>
                    <measurement group_id="B2" value="52.2" spread="9.3" lower_limit="21" upper_limit="75"/>
                    <measurement group_id="B3" value="52.2" spread="10.2" lower_limit="21" upper_limit="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Aortic Pulse Pressure (APP) in Intention to Treat (ITT) Population at Week 12</title>
        <description>The APP was calculated as aortic systolic pressure minus aortic diastolic pressure. The change in APP at Week 12 was calculated as APP at Week 12 minus APP at baseline.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>ITT population included all participants who had received at least 1 dose of the study medication or comparator and at least 1 post-dose measurement of aortic pulse pressure. &quot;n&quot; signifies those participants who were evaluated for this measure at the specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Bisoprolol</title>
            <description>Single dose of bisoprolol tablet (CONCOR®) administered orally at a dose of 5 milligram (mg) daily every morning for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Atenolol</title>
            <description>Single dose of atenolol tablet (TENORMIN®) administered orally at a dose of 50 mg daily every morning for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Aortic Pulse Pressure (APP) in Intention to Treat (ITT) Population at Week 12</title>
          <description>The APP was calculated as aortic systolic pressure minus aortic diastolic pressure. The change in APP at Week 12 was calculated as APP at Week 12 minus APP at baseline.</description>
          <population>ITT population included all participants who had received at least 1 dose of the study medication or comparator and at least 1 post-dose measurement of aortic pulse pressure. &quot;n&quot; signifies those participants who were evaluated for this measure at the specified time point.</population>
          <units>Millimeter of mercury (mmHg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=96, 95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.49" spread="11.33"/>
                    <measurement group_id="O2" value="45.93" spread="11.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in APP at Week 12 (n=90, 89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.40" spread="9.29"/>
                    <measurement group_id="O2" value="-3.69" spread="8.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in APP at Week 12: p-value was calculated by 2 sided t-test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5943</p_value>
            <p_value_desc>No adjustment of p-value was done and priori threshold was 0.05.</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.701</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.89</ci_lower_limit>
            <ci_upper_limit>3.29</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Aortic Blood Pressure (BP) at Week 4 and Week 12</title>
        <description>The change in aortic BP (aortic systolic blood pressure [SBP], aortic diastolic blood pressure [DBP] and aortic mean blood pressure [BP]) at Week 4 and Week 12 was calculated as aortic BP (aortic SBP, aortic DBP and aortic mean BP) at Week 4 and Week 12 minus aortic BP (aortic SBP, aortic DBP and aortic mean BP) at baseline.</description>
        <time_frame>Baseline, Week 4 and Week 12</time_frame>
        <population>ITT population included all participants who had received at least 1 dose of the study medication or comparator and at least 1 post-dose measurement of aortic pulse pressure. &quot;n&quot; signifies those participants who were evaluated for this measure at the specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Bisoprolol</title>
            <description>Single dose of bisoprolol tablet (CONCOR®) administered orally at a dose of 5 milligram (mg) daily every morning for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Atenolol</title>
            <description>Single dose of atenolol tablet (TENORMIN®) administered orally at a dose of 50 mg daily every morning for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Aortic Blood Pressure (BP) at Week 4 and Week 12</title>
          <description>The change in aortic BP (aortic systolic blood pressure [SBP], aortic diastolic blood pressure [DBP] and aortic mean blood pressure [BP]) at Week 4 and Week 12 was calculated as aortic BP (aortic SBP, aortic DBP and aortic mean BP) at Week 4 and Week 12 minus aortic BP (aortic SBP, aortic DBP and aortic mean BP) at baseline.</description>
          <population>ITT population included all participants who had received at least 1 dose of the study medication or comparator and at least 1 post-dose measurement of aortic pulse pressure. &quot;n&quot; signifies those participants who were evaluated for this measure at the specified time point.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change in aortic SBP at Week 4 (n=96, 95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.90" spread="12.68"/>
                    <measurement group_id="O2" value="-13.57" spread="12.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in aortic SBP at Week 12 (n=90, 89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.34" spread="15.11"/>
                    <measurement group_id="O2" value="-12.71" spread="14.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in aortic DBP at Week 4 (n=96, 95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.86" spread="8.23"/>
                    <measurement group_id="O2" value="-9.47" spread="8.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in aortic DBP at Week 12 (n=90, 89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.94" spread="9.53"/>
                    <measurement group_id="O2" value="-9.01" spread="8.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in aortic mean BP at Week 4 (n=96, 95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.88" spread="8.60"/>
                    <measurement group_id="O2" value="-10.84" spread="9.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in aortic mean BP at Week 12 (n=90, 89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.41" spread="10.84"/>
                    <measurement group_id="O2" value="-10.24" spread="10.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in SBP at Week 4: p-value was calculated by 2 sided t-test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8589</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in SBP at Week 12: p-value was calculated by 2 sided t-test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2223</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in DBP at Week 4: p-value was calculated by 2 sided t-test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2443</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in DBP at Week 12: p-value was calculated by 2 sided t-test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1481</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in mean BP at Week 4: p-value was calculated by 2 sided t-test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4188</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in mean BP at Week 12: p-value was calculated by 2 sided t-test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1586</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Aortic Augmentation Index (AIx) at Week 4 and Week 12</title>
        <description>Augmentation index is a composite measure of wave reflection and systemic arterial stiffness which was calculated as the difference between the second and first systolic peaks. The change in AIx at Week 4 and Week 12 was calculated as AIx at Week 4 and Week 12 minus AIx at baseline.</description>
        <time_frame>Baseline, Week 4 and Week 12</time_frame>
        <population>ITT population included all participants who had received at least 1 dose of the study medication or comparator and at least 1 post-dose measurement of aortic pulse pressure. &quot;n&quot; signifies those participants who were evaluated for this measure at the specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Bisoprolol</title>
            <description>Single dose of bisoprolol tablet (CONCOR®) administered orally at a dose of 5 milligram (mg) daily every morning for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Atenolol</title>
            <description>Single dose of atenolol tablet (TENORMIN®) administered orally at a dose of 50 mg daily every morning for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Aortic Augmentation Index (AIx) at Week 4 and Week 12</title>
          <description>Augmentation index is a composite measure of wave reflection and systemic arterial stiffness which was calculated as the difference between the second and first systolic peaks. The change in AIx at Week 4 and Week 12 was calculated as AIx at Week 4 and Week 12 minus AIx at baseline.</description>
          <population>ITT population included all participants who had received at least 1 dose of the study medication or comparator and at least 1 post-dose measurement of aortic pulse pressure. &quot;n&quot; signifies those participants who were evaluated for this measure at the specified time point.</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change in AIx at Week 4 (n=96, 95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.56" spread="10.43"/>
                    <measurement group_id="O2" value="-0.01" spread="10.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in AIx at Week 12 (n=90, 89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.61" spread="9.18"/>
                    <measurement group_id="O2" value="1.21" spread="9.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in AIx at Week 4: p-value was calculated by 2 sided t-test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2987</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in AIx at Week 12: p-value was calculated by 2 sided t-test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6584</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Carotid-femoral Pulse Wave Velocity (cfPWV) at Week 4 and Week 12</title>
        <description>Pulse wave velocity (PWV) is used as a measure of arterial stiffness, which is a measure of the cushioning functioning of major vessels like the aorta. The velocity of the Pulse wave (PW) along an artery is dependent on the stiffness of that artery. The change in cfPWV at Week 4 and Week 12 was calculated as cfPWV at Week 4 and Week 12 minus cfPWV at baseline.</description>
        <time_frame>Baseline, Week 4 and Week 12</time_frame>
        <population>ITT population included all participants who had received at least 1 dose of the study medication or comparator and at least 1 post-dose measurement of aortic pulse pressure. &quot;n&quot; signifies those participants who were evaluated for this measure at the specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Bisoprolol</title>
            <description>Single dose of bisoprolol tablet (CONCOR®) administered orally at a dose of 5 milligram (mg) daily every morning for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Atenolol</title>
            <description>Single dose of atenolol tablet (TENORMIN®) administered orally at a dose of 50 mg daily every morning for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Carotid-femoral Pulse Wave Velocity (cfPWV) at Week 4 and Week 12</title>
          <description>Pulse wave velocity (PWV) is used as a measure of arterial stiffness, which is a measure of the cushioning functioning of major vessels like the aorta. The velocity of the Pulse wave (PW) along an artery is dependent on the stiffness of that artery. The change in cfPWV at Week 4 and Week 12 was calculated as cfPWV at Week 4 and Week 12 minus cfPWV at baseline.</description>
          <population>ITT population included all participants who had received at least 1 dose of the study medication or comparator and at least 1 post-dose measurement of aortic pulse pressure. &quot;n&quot; signifies those participants who were evaluated for this measure at the specified time point.</population>
          <units>Meters per second (m/s)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change in cfPWV at Week 4 (n=96, 95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.60" spread="1.33"/>
                    <measurement group_id="O2" value="-0.81" spread="1.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change cfPWV at Week 12 (n=90, 89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.72" spread="1.40"/>
                    <measurement group_id="O2" value="-0.87" spread="1.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in cfPWV at Week 4: p-value was calculated by 2 sided t-test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2511</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in cfPWV at Week 12: p-value was calculated by 2 sided t-test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5007</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Heart Rate at Week 4 and Week 12</title>
        <description>The change in heart rate at Week 4 and Week 12 was calculated as heart rate at Week 4 and Week 12 minus heart rate at baseline.</description>
        <time_frame>Baseline, Week 4 and Week 12</time_frame>
        <population>ITT population included all participants who had received at least 1 dose of the study medication or comparator and at least 1 post-dose measurement of aortic pulse pressure. &quot;n&quot; signifies those participants who were evaluated for this measure at the specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Bisoprolol</title>
            <description>Single dose of bisoprolol tablet (CONCOR®) administered orally at a dose of 5 milligram (mg) daily every morning for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Atenolol</title>
            <description>Single dose of atenolol tablet (TENORMIN®) administered orally at a dose of 50 mg daily every morning for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Heart Rate at Week 4 and Week 12</title>
          <description>The change in heart rate at Week 4 and Week 12 was calculated as heart rate at Week 4 and Week 12 minus heart rate at baseline.</description>
          <population>ITT population included all participants who had received at least 1 dose of the study medication or comparator and at least 1 post-dose measurement of aortic pulse pressure. &quot;n&quot; signifies those participants who were evaluated for this measure at the specified time point.</population>
          <units>Beats per minute (bpm)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change in heart rate at Week 4 (n= 96, 95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.21" spread="7.72"/>
                    <measurement group_id="O2" value="-6.20" spread="8.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change heart rate at Week 12 (n= 90, 89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.64" spread="7.95"/>
                    <measurement group_id="O2" value="-7.84" spread="9.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in heart rate at Week 4: p-value was calculated by 2 sided t-test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9943</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in heart rate at Week 12: p-value was calculated by 2 sided t-test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5230</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Aortic Pulse Pressure (APP) at Week 4</title>
        <description>The APP was calculated as aortic systolic pressure minus aortic diastolic pressure. The change in APP at Week 4 was calculated as APP at Week 4 minus APP at baseline.</description>
        <time_frame>Baseline and Week 4</time_frame>
        <population>ITT population included all participants who had received at least 1 dose of the study medication or comparator and at least 1 post-dose measurement of aortic pulse pressure.</population>
        <group_list>
          <group group_id="O1">
            <title>Bisoprolol</title>
            <description>Single dose of bisoprolol tablet (CONCOR®) administered orally at a dose of 5 milligram (mg) daily every morning for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Atenolol</title>
            <description>Single dose of atenolol tablet (TENORMIN®) administered orally at a dose of 50 mg daily every morning for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Aortic Pulse Pressure (APP) at Week 4</title>
          <description>The APP was calculated as aortic systolic pressure minus aortic diastolic pressure. The change in APP at Week 4 was calculated as APP at Week 4 minus APP at baseline.</description>
          <population>ITT population included all participants who had received at least 1 dose of the study medication or comparator and at least 1 post-dose measurement of aortic pulse pressure.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.02" spread="10.56"/>
                    <measurement group_id="O2" value="-4.09" spread="8.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4447</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Lipid Levels at Week 12</title>
        <description>The lipid levels evaluated were total cholesterol, low density lipoprotein (LDL) cholesterol, and high density lipoprotein (HDL) cholesterol blood concentrations. The change in lipid levels at Week 12 was calculated as lipid levels at Week 12 minus lipid levels at baseline.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>ITT population included all participants who had received at least 1 dose of the study medication or comparator and at least 1 post-dose measurement of aortic pulse pressure.</population>
        <group_list>
          <group group_id="O1">
            <title>Bisoprolol</title>
            <description>Single dose of bisoprolol tablet (CONCOR®) administered orally at a dose of 5 milligram (mg) daily every morning for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Atenolol</title>
            <description>Single dose of atenolol tablet (TENORMIN®) administered orally at a dose of 50 mg daily every morning for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Lipid Levels at Week 12</title>
          <description>The lipid levels evaluated were total cholesterol, low density lipoprotein (LDL) cholesterol, and high density lipoprotein (HDL) cholesterol blood concentrations. The change in lipid levels at Week 12 was calculated as lipid levels at Week 12 minus lipid levels at baseline.</description>
          <population>ITT population included all participants who had received at least 1 dose of the study medication or comparator and at least 1 post-dose measurement of aortic pulse pressure.</population>
          <units>Milligram/decilitre (mg/dL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change in Total cholesterol at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.43" spread="23.35"/>
                    <measurement group_id="O2" value="-0.37" spread="24.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in LDL-cholesterol at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.29" spread="19.01"/>
                    <measurement group_id="O2" value="1.31" spread="17.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in HDL-cholesterol at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.58" spread="7.13"/>
                    <measurement group_id="O2" value="-3.02" spread="7.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in Total cholesterol at Week 12: p-value was calculated by 2 sided t-test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3960</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in LDL-cholesterol at Week 12: p-value was calculated by 2 sided t-test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1919</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in HDL-cholesterol at Week 12: p-value was calculated by 2 sided t-test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1896</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Blood Glucose Levels at Week 12</title>
        <description>The change in blood glucose level at Week 12 was calculated as blood glucose level at Week 12 minus blood glucose level at baseline.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>ITT population included all participants who had received at least 1 dose of the study medication or comparator and at least 1 post-dose measurement of aortic pulse pressure.</population>
        <group_list>
          <group group_id="O1">
            <title>Bisoprolol</title>
            <description>Single dose of bisoprolol tablet (CONCOR®) administered orally at a dose of 5 milligram (mg) daily every morning for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Atenolol</title>
            <description>Single dose of atenolol tablet (TENORMIN®) administered orally at a dose of 50 mg daily every morning for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Blood Glucose Levels at Week 12</title>
          <description>The change in blood glucose level at Week 12 was calculated as blood glucose level at Week 12 minus blood glucose level at baseline.</description>
          <population>ITT population included all participants who had received at least 1 dose of the study medication or comparator and at least 1 post-dose measurement of aortic pulse pressure.</population>
          <units>Millimoles per liter (mmol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.23" spread="17.85"/>
                    <measurement group_id="O2" value="-0.45" spread="12.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9244</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Brachial Blood Pressure (BP) at Week 4 and Week 12</title>
        <description>The change in brachial BP (brachial SBP, brachial DBP and brachial mean BP) at Week 4 and Week 12 was calculated as brachial BP (brachial SBP, brachial DBP and brachial mean BP) at Week 4 and Week 12 minus brachial BP (brachial SBP, brachial DBP and brachial mean BP) at baseline.</description>
        <time_frame>Baseline, Week 4 and Week 12</time_frame>
        <population>ITT population included all participants who had received at least 1 dose of the study medication or comparator and at least 1 post-dose measurement of aortic pulse pressure. &quot;n&quot; signifies those participants who were evaluated for this measure at the specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Bisoprolol</title>
            <description>Single dose of bisoprolol tablet (CONCOR®) administered orally at a dose of 5 milligram (mg) daily every morning for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Atenolol</title>
            <description>Single dose of atenolol tablet (TENORMIN®) administered orally at a dose of 50 mg daily every morning for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Brachial Blood Pressure (BP) at Week 4 and Week 12</title>
          <description>The change in brachial BP (brachial SBP, brachial DBP and brachial mean BP) at Week 4 and Week 12 was calculated as brachial BP (brachial SBP, brachial DBP and brachial mean BP) at Week 4 and Week 12 minus brachial BP (brachial SBP, brachial DBP and brachial mean BP) at baseline.</description>
          <population>ITT population included all participants who had received at least 1 dose of the study medication or comparator and at least 1 post-dose measurement of aortic pulse pressure. &quot;n&quot; signifies those participants who were evaluated for this measure at the specified time point.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change in brachial SBP at Week 4 (n=96, 95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.45" spread="11.74"/>
                    <measurement group_id="O2" value="-17.52" spread="12.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in brachial SBP at Week 12 (n=90, 89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.10" spread="14.55"/>
                    <measurement group_id="O2" value="-17.63" spread="13.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in brachial DBP at Week 4 (n=96, 95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.70" spread="9.01"/>
                    <measurement group_id="O2" value="-11.36" spread="8.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in brachial DBP at Week 12 (n=90, 89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.39" spread="9.90"/>
                    <measurement group_id="O2" value="-10.61" spread="8.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in brachial mean BP at Week 4 (n=96, 95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.28" spread="9.28"/>
                    <measurement group_id="O2" value="-13.41" spread="8.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in brachial mean BP at Week 12 (n=90, 89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.29" spread="10.78"/>
                    <measurement group_id="O2" value="-12.95" spread="9.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in SBP at Week 4: p-value was calculated by 2 sided t-test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9692</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in SBP at Week 12: p-value was calculated by 2 sided t-test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4731</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in DBP at Week 4: p-value was calculated by 2 sided t-test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2876</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in DBP at Week 12: p-value was calculated by 2 sided t-test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0420</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in mean BP at Week 4: p-value was calculated by 2 sided t-test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5100</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in mean BP at Week 12: p-value was calculated by 2 sided t-test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1207</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events (AEs)</title>
        <description>An adverse event (AE) was defined as any untoward medical occurrence in the form of signs, symptoms, abnormal laboratory findings, or diseases that emerges or worsens relative to baseline during a clinical study with an Investigational Medicinal Product (IMP), regardless of causal relationship and even if no IMP has been administered.</description>
        <time_frame>Baseline up to Week 14 (follow-up visit)</time_frame>
        <population>ITT population included all participants who had received at least 1 dose of the study medication or comparator and at least 1 post-dose measurement of aortic pulse pressure.</population>
        <group_list>
          <group group_id="O1">
            <title>Bisoprolol</title>
            <description>Single dose of bisoprolol tablet (CONCOR®) administered orally at a dose of 5 milligram (mg) daily every morning for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Atenolol</title>
            <description>Single dose of atenolol tablet (TENORMIN®) administered orally at a dose of 50 mg daily every morning for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events (AEs)</title>
          <description>An adverse event (AE) was defined as any untoward medical occurrence in the form of signs, symptoms, abnormal laboratory findings, or diseases that emerges or worsens relative to baseline during a clinical study with an Investigational Medicinal Product (IMP), regardless of causal relationship and even if no IMP has been administered.</description>
          <population>ITT population included all participants who had received at least 1 dose of the study medication or comparator and at least 1 post-dose measurement of aortic pulse pressure.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Aortic Pulse Pressure (APP) in Per Protocol (PP) Population at Week 12</title>
        <description>The APP was calculated as aortic systolic pressure minus aortic diastolic pressure. The change in APP at Week 12 was calculated as APP at Week 12 minus APP at baseline.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Per protocol (PP) population included those participants for whom primary and secondary efficacy endpoints were all measured, and who did not meet the withdrawal criteria and showed 75 percent of medication compliance.</population>
        <group_list>
          <group group_id="O1">
            <title>Bisoprolol</title>
            <description>Single dose of bisoprolol tablet (CONCOR®) administered orally at a dose of 5 milligram (mg) daily every morning for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Atenolol</title>
            <description>Single dose of atenolol tablet (TENORMIN®) administered orally at a dose of 50 mg daily every morning for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Aortic Pulse Pressure (APP) in Per Protocol (PP) Population at Week 12</title>
          <description>The APP was calculated as aortic systolic pressure minus aortic diastolic pressure. The change in APP at Week 12 was calculated as APP at Week 12 minus APP at baseline.</description>
          <population>Per protocol (PP) population included those participants for whom primary and secondary efficacy endpoints were all measured, and who did not meet the withdrawal criteria and showed 75 percent of medication compliance.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.87" spread="11.34"/>
                    <measurement group_id="O2" value="46.53" spread="11.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in APP at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.33" spread="9.66"/>
                    <measurement group_id="O2" value="-3.89" spread="9.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7561</p_value>
            <p_value_desc>No adjustment of p-value was done and priori threshold was 0.05.</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.442</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.36</ci_lower_limit>
            <ci_upper_limit>3.24</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline up to Week 14 (follow-up visit)</time_frame>
      <desc>An adverse event (AE) was defined as any untoward medical occurrence in the form of signs, symptoms, abnormal laboratory findings, or diseases that emerges or worsens relative to baseline during a clinical study with an Investigational Medicinal Product (IMP), regardless of causal relationship and even if no IMP has been administered.</desc>
      <group_list>
        <group group_id="E1">
          <title>Bisoprolol</title>
          <description>Single dose of bisoprolol tablet (CONCOR®) administered orally at a dose of 5 milligram (mg) daily every morning for 12 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Atenolol</title>
          <description>Single dose of atenolol tablet (TENORMIN®) administered orally at a dose of 50 mg daily every morning for 12 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>WHO-ART (Ver. 092)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Coronary artery disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Uterine carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache aggravated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Dizziness aggravated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>WHO-ART (Ver. 092)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiomegaly</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Dry eyes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Heartburn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Duodenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Polyposis gastric</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Common cold</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Tinea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>AV block first degree</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Bradyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Bladder irritability</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Ureteral calculus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Chest tightness of</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Chest pressure sensation of</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Pain groin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Face oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Hot flushes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Pain in limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Gallbladder disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Liver fatty</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperlipaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cramps</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Arthralgia aggravated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Pain neck/shoulder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Cartilage damage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Back pain aggravated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Uterine fibromyoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Eyelid fluttering</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Headache aggravated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Radiculopathy cervical</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Libido decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Sleepiness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Impotence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Rhinitis allergic atopic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Itching</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Sweating increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Skin cysts</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Merck KGaA Communication Center</name_or_title>
      <organization>Merck Serono, a division of Merck KGaA</organization>
      <phone>+49-6151-72-5200</phone>
      <email>service@merckgroup.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

